Related references
Note: Only part of the references are listed.The efficacy of ibrutinib in the treatment of Richter syndrome
Mazie Tsang et al.
BLOOD (2015)
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wyndham H. Wilson et al.
NATURE MEDICINE (2015)
Ibrutinib has some activity in Richter's syndrome
S. Giri et al.
BLOOD CANCER JOURNAL (2015)
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
Kami J. Maddocks et al.
JAMA ONCOLOGY (2015)
Ibrutinib and rituximab induced rapid response in refractory Richter syndrome
Zanetta Lamar et al.
CLINICAL CASE REPORTS (2015)
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Jason A. Dubovsky et al.
BLOOD (2013)
Paradoxical Immune Reconstitution Inflammatory Syndrome Associated With Rituximab-Containing Regimen in a Patient With Lymphoma
Jonathan Canaani et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis et al.
NATURE (2010)
Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: Proof of principle, description, and clinical and research implications
Marisa H. Miceli et al.
CANCER (2007)
Cryptococcal immune reconstitution inflammatory syndrome following alemtuzumab therapy
Paul R. Ingram et al.
CLINICAL INFECTIOUS DISEASES (2007)
Immune restoration disease after antiretroviral therapy
MA French et al.
AIDS (2004)
Immune reconstitution inflammatory syndrome - Emergence of a unique syndrome during highly active antiretroviral therapy
SA Shelburne et al.
MEDICINE (2002)
Share Paper
